Tilray Inc. Cl 2

NAS: TLRY

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Apr 3, 2020, 7:59 p.m.

/zigman2/quotes/209129655/composite

$

5.46

Change

-0.08 -1.44%

Volume

Volume 127,305

Quotes are delayed by 20 min

/zigman2/quotes/209129655/composite

Previous close

$ 6.10

$ 5.54

Change

-0.56 -9.18%

Day low

Day high

$5.50

$6.15

Open

52 week low

52 week high

$2.43

$61.56

Open

Company Description

Tilray, Inc. engages in the research, cultivation, production, and distribution of medical cannabis and cannabinoids. The Company is focused on medical cannabis research, cultivation, processing and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extract...

Tilray, Inc. engages in the research, cultivation, production, and distribution of medical cannabis and cannabinoids. The Company is focused on medical cannabis research, cultivation, processing and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment sales consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment sales consist of hemp seed, hemp foods, board spectrum hemp extract containing CBD which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Nanaimo, Canada.

Valuation

Price to Sales Ratio

10.31

Price to Book Ratio

6.17

Enterprise Value to EBITDA

-5.07

Enterprise Value to Sales

6.10

Total Debt to Enterprise Value

0.22

Efficiency

Revenue/Employee

101,445.00

Income Per Employee

-195,121.00

Receivables Turnover

5.52

Total Asset Turnover

0.22

Liquidity

Current Ratio

2.80

Quick Ratio

1.85

Cash Ratio

1.05

Profitability

Gross Margin

-21.02

Operating Margin

-129.69

Pretax Margin

-194.70

Net Margin

-192.34

Return on Assets

-41.36

Return on Equity

-133.01

Return on Total Capital

-31.36

Return on Invested Capital

-46.66

Capital Structure

Total Debt to Total Equity

164.46

Total Debt to Total Capital

62.19

Total Debt to Total Assets

52.34

Long-Term Debt to Equity

163.07

Long-Term Debt to Total Capital

61.66

Officers and Executives

Name Age Officer Since Title
Mr. Brendan Kennedy 46 2018 President, Chief Executive Officer & Director
Mr. Jon Levin 50 2020 Chief Operating Officer
Mr. Michael Kruteck 54 2020 Chief Financial Officer
Mr. Cuba Flowers - 2016
Dr. Joshua Eades - 2014 Chief Science Officer & Vice President

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
03/18/2020 Andrew Pucher
Chief Corporate Dev Officer
16,072   Derivative/Non-derivative trans. at $2.47 per share. 39,697
03/18/2020 Andrew Pucher
Chief Corporate Dev Officer
30,024   Derivative/Non-derivative trans. at $0 per share. 0
03/01/2020 Maryscott Greenwood
Director
2,187   Derivative/Non-derivative trans. at $0 per share. 0
03/01/2020 Rebekah Dopp
Director
2,187   Derivative/Non-derivative trans. at $0 per share. 0
03/01/2020 Christine Thompson St. Clare
Director
2,187   Derivative/Non-derivative trans. at $0 per share. 0
02/13/2020 Brendan Kennedy
President and CEO; Director
100,000   Disposition at $16.28 per share. 1,628,000
02/13/2020 Brendan Kennedy
President and CEO; Director
100,000   Derivative/Non-derivative trans. at $7.76 per share. 776,000
01/13/2020 Brendan Kennedy
President and CEO; Director
3,294   Disposition at $17.34 per share. 57,117
01/13/2020 Brendan Kennedy
President and CEO; Director
67,113   Disposition at $16.74 per share. 1,123,471
01/13/2020 Brendan Kennedy
President and CEO; Director
29,593   Disposition at $15.52 per share. 459,283
01/01/2020 Brendan Kennedy
President and CEO; Director
13,899   Derivative/Non-derivative trans. at $17.13 per share. 238,089
01/01/2020 Edward Wood Pastorius
Chief Revenue Officer
2,135   Derivative/Non-derivative trans. at $17.13 per share. 36,572
01/01/2020 Brendan Kennedy
President and CEO; Director
46,875   Derivative/Non-derivative trans. at $0 per share. 0
01/01/2020 Michael Shtender-Auerbach
Director
2,187   Derivative/Non-derivative trans. at $0 per share. 0
01/01/2020 Edward Wood Pastorius
Chief Revenue Officer
6,250   Derivative/Non-derivative trans. at $0 per share. 0
12/12/2019 Michael Shtender-Auerbach
Director
2,130,577   Award at $0 per share. 0
12/12/2019 Michael Shtender-Auerbach
Director
833,351   Award at $0 per share. 0
12/12/2019 Michael Shtender-Auerbach
Director
476,641   Award at $0 per share. 0
12/12/2019 Edward Wood Pastorius
Chief Revenue Officer
41,015   Award at $0 per share. 0
12/12/2019 Edward Wood Pastorius
Chief Revenue Officer
49,985   Award at $0 per share. 0
12/12/2019 Edward Wood Pastorius
Chief Revenue Officer
61,729   Award at $0 per share. 0
12/11/2019 Brendan Kennedy
President and CEO; Director
100,000   Disposition at $18.3 per share. 1,830,000
12/02/2019 Michael Shtender-Auerbach
Director
900   Disposition at $19.81 per share. 17,829
12/02/2019 Michael Shtender-Auerbach
Director
7,537   Disposition at $19.05 per share. 143,579
12/02/2019 Michael Shtender-Auerbach
Director
31,875   Disposition at $19.05 per share. 607,218
12/02/2019 Michael Shtender-Auerbach
Director
18,750   Derivative/Non-derivative trans. at $7.76 per share. 145,500
12/01/2019 Maryscott Greenwood
Director
2,188   Derivative/Non-derivative trans. at $0 per share. 0
12/01/2019 Rebekah Dopp
Director
2,188   Derivative/Non-derivative trans. at $0 per share. 0
12/01/2019 Christine Thompson St. Clare
Director
2,188   Derivative/Non-derivative trans. at $0 per share. 0
10/01/2019 Brendan Kennedy
President and CEO; Director
18,461   Derivative/Non-derivative trans. at $24.18 per share. 446,386
10/01/2019 Edward Wood Pastorius
Chief Revenue Officer
2,749   Derivative/Non-derivative trans. at $24.18 per share. 66,470
10/01/2019 Brendan Kennedy
President and CEO; Director
46,875   Derivative/Non-derivative trans. at $0 per share. 0
10/01/2019 Michael Shtender-Auerbach
Director
2,188   Derivative/Non-derivative trans. at $0 per share. 0
10/01/2019 Edward Wood Pastorius
Chief Revenue Officer
6,250   Derivative/Non-derivative trans. at $0 per share. 0
/news/latest/company/us/tlry

MarketWatch News on TLRY

  1. As the Covid-19 Crisis Deepens, U.S. Pot Producers Prosper

    1:29 p.m. April 2, 2020

    - Bill Alpert

  2. Tilray says to rlease 11 mln class 2 shares from lock-up agreement

    8:01 a.m. March 31, 2020

    - Ciara Linnane

  3. Pot stocks plunge after another round of disappointing earnings

    2:48 p.m. March 30, 2020

    - Max A. Cherney

  4. Tilray stock price target cut to $3.90 from $14.50 at Stifel Nicolaus

    7:33 a.m. March 16, 2020

    - Tomi Kilgore

  5. Tilray stock slides 27% after pricing $90 million equity offering

    12:31 p.m. March 13, 2020

    - Max A. Cherney

  6. Tesla Jumps, Tilray Slumps, and the Stock Market Is Really Volatile

    8:44 a.m. March 3, 2020

    - Carleton English

  7. Tilray stock price target cut to $28 from $40 at Benchmark

    7:56 a.m. March 3, 2020

    - Tomi Kilgore

  8. Tilray stock price target cut to $14.50 from $18.00 at Stifel Nicolaus

    7:43 a.m. March 3, 2020

    - Tomi Kilgore

  9. Tilray stock price target cut to $15 from $18 at Alliance Global Partners

    7:40 a.m. March 3, 2020

    - Tomi Kilgore

  10. Loading more headlines...
/news/nonmarketwatch/company/us/tlry

Other News on TLRY

  1. Below $1, Is Aurora Stock Finally a Buy?

    8:30 a.m. April 3, 2020

    - InvestorPlace.com

  2. Aurora Cannabis Stock Still Is Trouble — and Peers Show Why

    10:55 a.m. April 1, 2020

    - InvestorPlace.com

  3. Plans for NY legal pot up in smoke

    5:24 a.m. April 1, 2020

    - Seeking Alpha

  4. AMRN, CCL among premarket losers

    9:19 a.m. March 31, 2020

    - Seeking Alpha

  5. Tilray Stock Dives as Shares Released From Lockup Period

    9:02 a.m. March 31, 2020

    - 247WallSt.com

  6. Are Marijuana Stocks & ETFs Coronavirus-Proof?

    1:00 p.m. March 27, 2020

    - Zacks.com

  7. Why Tilray Stock Is Soaring Again After a Terrible Year

    12:03 p.m. March 27, 2020

    - 247WallSt.com

  8. Pot stocks side step broad market selloff

    10:29 a.m. March 27, 2020

    - Seeking Alpha

  9. TLRY, HEXO among premarket gainers

    9:16 a.m. March 27, 2020

    - Seeking Alpha

  10. Stock Market Today: Record Jobless Claims; Apple 5G iPhone Delay?

    4:19 p.m. March 26, 2020

    - InvestorPlace.com

  11. TLRY, LADR, WLL and RKDA among midday movers

    12:43 p.m. March 26, 2020

    - Seeking Alpha

  12. Pot names on the move as sales stay strong

    11:13 a.m. March 26, 2020

    - Seeking Alpha

  13. NRZ, TLRY among premarket gainers

    9:16 a.m. March 26, 2020

    - Seeking Alpha

  14. Virgin Galactic Stock Is a Buy — With Money You Can Afford to Lose

    3:01 p.m. March 24, 2020

    - InvestorPlace.com

  15. BA and DAL among premarket gainers

    9:14 a.m. March 24, 2020

    - Seeking Alpha

  16. Legal pot in NY still on track - Gov. Cuomo

    12:24 p.m. March 23, 2020

    - Seeking Alpha

  17. BMY, TLRY among premarket gainers

    9:21 a.m. March 23, 2020

    - Seeking Alpha

  18. Tilray Is Flirting with Disaster

    8:05 a.m. March 20, 2020

    - InvestorPlace.com

  19. It’s Too Early to Buy Into the Boeing Bailout

    10:16 a.m. March 19, 2020

    - InvestorPlace.com

  20. Loading more headlines...

At a Glance

Tilray, Inc.

1100 Maughan Road

Nanaimo, British Columbia V9X IJ2

Phone

1 8448457291

Industry

Farming

Sector

Agriculture

Fiscal Year-end

12/2020

Revenue

$166.98M

Net Income

$-321.17M

2019 Sales Growth

287.2%

Employees

1,646

/news/pressrelease/company/us/tlry

Press Releases on TLRY

  1. Tilray, Inc. (TLRY) Releases 11 Million Shares From Lock-Up Agreement

    8:22 a.m. March 31, 2020

    - Marijuana Stocks

  2. Tilray, Inc. Releases 11 Million Shares From Lock-Up Agreement

    8:00 a.m. March 31, 2020

    - BusinessWire - BZX

  3. Loading more headlines...
Link to MarketWatch's Slice.